Paying for Mental Health Care

Ketamine Clinic vs. Spravato: The Coverage Decision

Save

For coverage, Spravato is usually the likelier bet — it is FDA-approved for treatment-resistant depression, so plans have a pathway to pay under criteria. Ketamine-clinic infusions are typically off-label and cash-pay. The right choice still depends on totaling each full course against your real out-of-pocket costs.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Which one is my insurance more likely to help with?

If the deciding factor is coverage, the answer usually leans toward Spravato. As an FDA-approved esketamine treatment for treatment-resistant depression, it has a defined pathway for insurers to pay when the criteria are met — documented antidepressant trials, the treatment-resistant diagnosis, and a certified center 4. Ketamine-clinic infusions for depression are generally used off-label and are far more often billed as cash-pay. That does not make the decision automatic, because covered still comes with constraints and your cost-share, but it does mean the two paths start from very different places on your bill. Reading why the coverage asymmetry exists explains the rule underneath this comparison.

How do you compare them on total cost, not per session?

A single-session price is misleading, because both treatments are courses rather than one-off visits. The honest comparison totals a full course on each side. For Spravato, that means your cost-share across the induction and any continued dosing once coverage applies; for infusions, it means the cash price of the series a clinic recommends. Research comparing esketamine with intravenous ketamine treats them as distinct options with distinct cost structures, so you cannot port one's math onto the other 1. Cost-effectiveness analyses of esketamine model it over a treatment course, not a single dose 2. Pricing a full infusion course against your Spravato cost-share is the apples-to-apples version of this question.

What does "covered but constrained" really mean?

Covered is not the same as effortless. Even when a plan pays for Spravato, you still work within its guardrails: meeting the treatment-resistant criteria, pairing it with an oral antidepressant, using a certified center, and covering your share of the cost. Those constraints are the trade for a lower out-of-pocket total. Cash-pay infusions invert the deal — fewer coverage hoops and more scheduling freedom, but the full price is yours. Neither is universally better; they are different bargains. Framing the choice as lower cost with more rules versus more flexibility at full price tends to make the trade-off clearer than treating one as simply cheaper. Confirming what your plan pays for Spravato fills in the covered side of that ledger.

How do you get real numbers for each path?

The comparison only works with your own figures, not online averages. For the covered path, the clinic's billing office and your plan can estimate your cost-share for a Spravato course once benefits apply. For the cash-pay path, an infusion clinic must give uninsured or self-pay patients a good faith estimate of expected charges before scheduled care, with a dispute process if the final bill substantially exceeds it 3. Requesting both, in writing, turns the decision from a guess into a side-by-side. It is also fair to ask each clinic what a typical full course looks like for someone in your situation, so you are comparing complete plans rather than mismatched fragments. Two written estimates make the trade-off visible in dollars you can actually weigh.

When a clinician helps you make the call

Cost framing narrows the field, but the final choice belongs in a conversation with a clinician who knows your history. The coverage math can tell you which path is lighter on your wallet; only your prescriber can weigh that against what is clinically reasonable for you, and this page does not try to make that call. If you use Gale to connect with a provider, you can bring both written estimates and ask which approach fits your situation and your budget together. And if cost is the real barrier on either path, that is worth naming directly — clinics and manufacturers sometimes offer assistance programs, and knowing your true numbers is what makes those conversations productive rather than abstract.

Common questions

Usually Spravato. It is FDA-approved for treatment-resistant depression, so plans have a pathway to pay when criteria are met, while ketamine-clinic infusions for depression are typically off-label and cash-pay 4. That said, Spravato's coverage still comes with constraints and your cost-share, so covered is not the same as free.

Compare full courses, not single sessions. For Spravato, that is your cost-share across induction and continued dosing once covered; for infusions, it is the cash price of the recommended series 12. Getting a written estimate for each — from the clinic's billing office and from the infusion clinic — gives you an apples-to-apples total.

Even when a plan pays for Spravato, you work within its rules: the treatment-resistant criteria, pairing with an oral antidepressant, a certified center, and your share of the cost. Those constraints are the trade for a lower out-of-pocket total, whereas cash-pay infusions offer more flexibility but the full price is yours.

Ask for written figures. The clinic's billing office and your plan can estimate your Spravato cost-share once benefits apply, and an infusion clinic must give self-pay patients a good faith estimate before scheduled care, with a dispute process if the bill substantially exceeds it 3. Two written estimates make the trade-off concrete.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

If things feel heavy, a person is available anytime — call or text 988.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

If the decision is stalling urgent care

  • —Thoughts of suicide, or of not wanting to be alive
  • —Putting off treatment while you compare coverage and cost
  • —A depression that is worsening faster than the decision timeline

Coverage and cost for Spravato and ketamine infusions depend on FDA approval status, your health plan, the clinic, and your clinical situation; this article describes general patterns, not your specific policy or care. It is general information, not medical or financial advice. If you are in crisis, call or text 988 (Suicide & Crisis Lifeline), free and available 24/7.

References

  1. 1.Brendle M et al. (2022). Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates. Journal of Affective Disorders. doi:10.1016/j.jad.2022.09.083 ✓esketamine-cost-effectivenessesketamine-vs-iv-ketamineinterventional-psychiatry-cost
  2. 2.Ross EL & Soeteman DI (2020). Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States. Psychiatric Services. doi:10.1176/appi.ps.201900625 ✓esketamine-cost-effectivenessspravato-accesstreatment-resistant-depression-cost
  3. 3.Centers for Medicare & Medicaid Services (2022). Overview of rules & fact sheets (No Surprises Act). CMS.gov (No Surprises Act). link ✓
  4. 4.Agboola F et al. (2020). The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression. Journal of Managed Care & Specialty Pharmacy (JMCP). doi:10.18553/jmcp.2020.26.1.16 ✓esketamine-cost-effectivenessesketamine-value-assessmenticer-reporttreatment-resistant-depression-cost

4 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library